Skip to main content

Advertisement

Table 1 Patient characteristics

From: Dose-volume analysis of predictors for acute anal toxicity after radiotherapy in prostate cancer patients

  Training group (N = 248 cases) Validation group (N = 99 cases)
Factors NAAT AAT P NAAT AAT P
Age (%)
 46-68ys 72 (55.8) 57 (44.2) 0.117 44 (75.9) 14 (24.1) 0.067
 68-88ys 78 (65.5) 41 (34.5) 24 (58.5) 17 (41.5)
T stage (%)
 1~2 36 (56.3) 28 (43.7) 0.789 21 (67.7) 10 (32.3) 0.933
 3~4 114 (62.0) 70 (38.0) 45 (69.2) 20 (30.8)
N stage (%)
 0 92 (64.3) 51 (35.7) 0.148 40 (65.6) 21 (34.4) 0.375
 1 58 (55.2) 47 (44.8) 26 (74.3) 9 (25.7)
M stage (%)
 0 90 (60.4) 59 (39.6) 0.974 48 (69.6) 21 (30.4) 0.775
 1 60 (60.6) 39 (39.4) 20 (66.7) 10 (33.3)
Clinical stage (%)
 I~II 23 (54.8) 19 (45.2) 0.753 18 (66.7) 9 (33.3) 0.880
 III~IV 127 (61.7) 79 (38.3) 50 (69.4) 22 (30.6)
GS group (%)
 6~7 66 (64.7) 36 (35.3) 0.256 25 (80.6) 6 (19.4) 0.074
 8~10 84 (57.5) 62 (42.5) 40 (62.5) 24 (37.5)
TPSA before treatment (%)
  < 20 ng/mL 22 (59.5) 15 (40.5) 0.890 40 (62.5) 24 (37.5) 0.226
  ≥ 20 ng/mL 128 (60.7) 83 (39.3) 19 (76.0) 6 (24.0)
TPSA before RT (%)·
  < 20 ng/mL 119 (60.1) 79 (39.9) 0.806 61 (67.0) 30 (33.0) 0.407
  ≥ 20 ng/mL 31 (62.0) 19 (28.0) 5 (83.3) 1 (16.7)
RT type (%)
 IMRT/VMAT 23 (67.6) 11 (32.4) 0.358 5 (50.0) 5 (50.0) 0.179
 IMRT/VMAT-IGRT 127 (59.3) 87 (40.7) 63 (70.8) 26 (29.2)
RT modality (%)
 Conventional fraction 126 (62.1) 77 (37.9) 0.278 46 (66.7) 23 (33.3) 0.511
 Hypo-fraction 24 (53.3) 21 (46.7) 22 (73.3) 8 (26.7)
Surgery (%)
 No 94 (61.4) 59 (38.6) 0.697 31 (62.0) 19 (38.0) 0.483
 Yes 56 (58.9) 39 (41.1) 33 (68.8) 15 (31.3)
Hormonal treatment duration (%)
  < 2 years 23 (54.8) 19 (45.2) 0.405 17 (63.0) 10 (37.0) 0.730
  ≥ 2 years 127 (61.7) 79 (38.3) 48 (66.7) 24 (33.3)
Hemorrhoid (%)
 NO 95 (87.2) 14 (12.8) < 0.001 39 (83.0) 8 (17.0) 0.004
 Yes 55 (39.6) 84 (60.4) 29 (55.8) 23 (44.2)
  1. Abbreviations: GS Gleason score; TPSA total prostate-specific antigen; RT radiation therapy